AI study to predict genetic changes in myeloma cells
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial uses artificial intelligence to look at individual myeloma cells under a microscope to predict genetic abnormalities (FISH results). It may help doctors understand your myeloma better without waiting for a separate FISH test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma as defined by current Chinese medical guidelines.
- You cannot have a condition that is not multiple myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This trial tests if an artificial intelligence (AI) program can help people with blood cancer learn about their condition and treatment. The goal is to see if AI-assisted education improves their understanding and care.
This study uses artificial intelligence to analyze how multiple myeloma may lead to early relapse. It may help doctors better predict and manage the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.